

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM862795

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	MERGER AND CHANGE OF NAME		
<b>EFFECTIVE DATE:</b>	12/07/2022		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
HORIZON THERAPEUTICS, LLC		12/07/2022	Limited Liability Company: DELAWARE
<b>NEWLY MERGED ENTITY DATA</b>			
<b>Name</b>	<b>Execution Date</b>	<b>Entity Type</b>	
HORIZON ORPHAN LLC	12/07/2022	Limited Liability Company: DELAWARE	
<b>MERGED ENTITY'S NEW NAME (RECEIVING PARTY)</b>			
<b>Name:</b>	HORIZON THERAPEUTICS U.S. HOLDING LLC		
<b>Street Address:</b>	1 Horizon Way		
<b>City:</b>	Deerfield		
<b>State/Country:</b>	ILLINOIS		
<b>Postal Code:</b>	60015		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4324829	RAVICTI	
<b>Registration Number:</b>	2203912	BUPHENYL	
<b>Registration Number:</b>	5681115	UCD IN COMMON	
<b>Registration Number:</b>	5397670		
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2122919868		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	(212) 558-4229		
<b>Email:</b>	demarcor@sullcrom.com, nguyenb@sullcrom.com, maken@sullcrom.com		
<b>Correspondent Name:</b>	Raffaele A. DeMarco		
<b>Address Line 1:</b>	125 Broad Street		
<b>Address Line 2:</b>	Sullivan & Cromwell LLP		
<b>Address Line 4:</b>	New York, NEW YORK 10004		

OP \$115.00 4324829

<b>NAME OF SUBMITTER:</b>	Raffaele DeMarco
<b>SIGNATURE:</b>	/Raffaele A. DeMarco/
<b>DATE SIGNED:</b>	12/21/2023
<b>Total Attachments: 3</b> source=2.(ii) Horizon Therapeutics LLC into Horizon Orphan LLC 4870-5923-5207 v.1#page1.tif source=2.(ii) Horizon Therapeutics LLC into Horizon Orphan LLC 4870-5923-5207 v.1#page2.tif source=2.(ii) Horizon Therapeutics LLC into Horizon Orphan LLC 4870-5923-5207 v.1#page3.tif	

# Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"HORIZON THERAPEUTICS, LLC", A DELAWARE LIMITED LIABILITY COMPANY,

WITH AND INTO "HORIZON ORPHAN LLC" UNDER THE NAME OF "HORIZON THERAPEUTICS U.S. HOLDING LLC", A LIMITED LIABILITY COMPANY ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE ON THE SEVENTH DAY OF DECEMBER, A.D. 2022, AT 6:11 O`CLOCK P.M.



  
Jeffrey W. Bullock, Secretary of State

4244171 8100M  
SR# 20233700640

You may verify this certificate online at [corp.delaware.gov/authver.shtml](http://corp.delaware.gov/authver.shtml)

Authentication: 204345030  
Date: 10-10-23

**TRADEMARK**  
**REEL: 008296 FRAME: 0758**

State of Delaware  
 Secretary of State  
 Division of Corporations  
 Delivered 06:11 PM 12/07/2022  
 FILED 06:11 PM 12/07/2022  
 SR 20224206442 - File Number 4396007

**CERTIFICATE OF MERGER  
 OF  
 HORIZON THERAPEUTICS, LLC  
 WITH AND INTO  
 HORIZON ORPHAN LLC**

**December 7, 2022**

Pursuant to Section 18-209 of the Delaware Limited Liability Company Act (“DLLCA”), Horizon Orphan LLC, a Delaware limited liability company, does hereby certify the following information in connection with the merger of Horizon Therapeutics, LLC, a Delaware limited liability company (the “Merger”):

**FIRST:** The name and state of formation of each of the constituent entities in the Merger are as follows:

<u>Name</u>	<u>State of Formation</u>
Horizon Therapeutics, LLC	Delaware
Horizon Orphan LLC	Delaware

**SECOND:** The Agreement and Plan of Merger, dated as of December 7, 2022 by and between Horizon Therapeutics, LLC and Horizon Orphan LLC (as amended, modified, and supplemented from time to time, the “Merger Agreement”) has been approved, adopted, executed, certified and acknowledged by each of the parties pursuant to and in accordance with the requirements of Section 18-209 of the DLLCA.

**THIRD:** The name of the surviving entity in the Merger (the “Surviving Entity”) shall be “Horizon Therapeutics U.S. Holding LLC”.

**FOURTH:** The certificate of formation of Horizon Orphan LLC as in effect immediately prior to the Merger shall be the certificate of formation of the Surviving Entity, except that the text of Article I thereof shall be deleted in its entirety and replaced by substituting in lieu of said Article I the following new Article I as follows:

“The name of the limited liability company is Horizon Therapeutics U.S. Holding LLC (the “*Company*”).”


**FIFTH:** The executed Merger Agreement is on file at the principal place of business of the Surviving Entity, the address of which is 1 Horizon Way, Deerfield, Illinois, 60015.

**SIXTH:** A copy of the Merger Agreement will be furnished by the Surviving Entity, on request and without cost, to any member of either Horizon Therapeutics, LLC or Horizon Orphan LLC.

**SEVENTH:** The Merger shall become effective immediately upon the filing of this Certificate of Merger with the Secretary of State of the State of Delaware.

**IN WITNESS WHEREOF**, the undersigned has executed this Certificate of Merger on the date first written above.

**HORIZON ORPHAN LLC**

By:  \_\_\_\_\_  
Name: Timothy P. Walbert  
Title: President and Chief Executive Officer

[SIGNATURE PAGE TO DELAWARE CERTIFICATE OF MERGER]